Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$20.89 + 0.21
Stock chart for: PTLA.O.  Currently trading at $20.89 with a 52 week high of $56.70 and a 52 week low of $18.18.
12/10/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Portola Pharmaceuticals, Inc. at the Citi’s Global Healthcare Conference
Thursday, December 6, 2018
LocationNew York, NY

Portola Pharmaceuticals, Inc. at Credit Suisse’s 27th Annual Healthcare Conference
Tuesday, November 13, 2018 2:50 p.m. MT
LocationScottsdale, AZ